FoxBioPath SRL
The score of FoxBioPath shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
FoxBioPath's annual accounts
| 2025 | |
|---|---|
| Net result | 66,668 € |
| Equity | 71,668 € |
| Cash | 79,587 € |
| EBITDA | 83,538 € |
| Total assets | 103,842 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Jun 2026
FoxBioPath's financial analysis
- Solvency69.0%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of FoxBioPath
FoxBioPath's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1025.117.675
- VAT number
- BE1025117675
- Peppol
- Registered · 0208:1025117675 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 03 Jul 2025
- Registered office
- 2570 Duffel
- Latest accounts
- 2025 · filed on 28 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
FoxBioPath (SRL) has been based in Duffel since 2025, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 66,668 € and equity of 71,668 €; its revenue is not published. Its solvency stands at 69.0%, above the median of its sector (60.4%).
Companies similar to FoxBioPath
Companies in the same business, of comparable size and area, outside its group.
- Consultbio Research and experimental development on natural sciences and engineering Rumst · balance sheet 106,674 €
- NuStats Lab Research and experimental development on natural sciences and engineering Erpe-Mere · balance sheet 118,033 €
- ReWrite Research and experimental development on natural sciences and engineering Leuven · balance sheet 115,374 €
- Biograbbit Research and experimental development on natural sciences and engineering Dendermonde · balance sheet 61,503 €
- 1991 Southern Sky Research and experimental development on natural sciences and engineering Anderlecht · balance sheet 77,620 €
- Bio-Perspectives Research and experimental development on natural sciences and engineering Ixelles · balance sheet 206,760 €
- ComPro Pharma Research and experimental development on natural sciences and engineering Sprimont · balance sheet 76,879 €
- Opero Research and experimental development on natural sciences and engineering Grimbergen · balance sheet 225,981 €
Frequently asked questions about FoxBioPath
What is the revenue of FoxBioPath?
FoxBioPath files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of FoxBioPath?
In Belgium, the VAT number is the company number prefixed with BE: BE1025117675 for FoxBioPath, if the company is VAT-registered. Its company number (CBE) is 1025.117.675.
Where is the registered office of FoxBioPath?
According to the CBE register, the registered office of FoxBioPath is in 2570 Duffel.
What is the equity of FoxBioPath?
At the close of the 2025 financial year, the equity of FoxBioPath amounts to 71,668 €, a solvency of 69.0% of total assets.
Who manages FoxBioPath?
The register lists 1 active mandates at FoxBioPath. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of FoxBioPath
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →